Drugs / Pumitamig
Pumitamig
Trials 40 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/216 trials | ||||||
| Phase 1/2 | NCT07579221 | Nov 2026 → Aug 2029 expected | non-small cell lung carcinoma | M.D. Anderson Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07293351 | Mar 2026 → Nov 2029 expected | renal cell carcinoma | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07291076 | Mar 2026 → Oct 2029 expected | hepatocellular carcinoma | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07325136 | Feb 2026 → Apr 2029 expected | small cell lung carcinoma | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07111520 | Sep 2025 → Jan 2029 expected | non-small cell lung carcinoma | BioNTech SE | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07147348 | Aug 2025 → Nov 2027 expected | neoplastic disease or syndrome | BioNTech SE | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07070232 | Aug 2025 → Feb 2028 expected | neoplasm | BioNTech SE | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07079631 | Jul 2025 → Dec 2030 expected | colorectal cancer | BioNTech SE | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06892548 | May 2025 → Sep 2028 expected | lung cancer | BioNTech SE | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06827236 | Apr 2025 → Aug 2029 expected | breast carcinoma | BioNTech SE | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06618287 | Feb 2025 → Feb 2031 expected | breast cancer, lung cancer | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06584071 | Dec 2024 → Oct 2026 expected | hepatocellular carcinoma | BioNTech SE | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05438329 | Jul 2022 → Aug 2027 expected | neoplasm | DualityBio Inc. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05918133 | Jul 2022 → Oct 2026 expected | triple-negative breast carcinoma | BioNTech SE | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04895709 | May 2021 → Aug 2031 expected | cervical cancer, colorectal cancer, gastroesophageal adenocarcinoma, head and neck squamous cell carcinoma +7 | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05918445 | Mar 2021 → Nov 2025 overdue | cancer | BioNTech SE | Recruiting | No outcome recorded |
| Phase 215 trials | ||||||
| Phase 2 | NCT07492680 | Jul 2026 → Aug 2028 expected | cancer | Bristol-Myers Squibb | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07297212 | Jan 2026 → Jan 2028 expected | IDH-wildtype glioblastoma | BioNTech SE | Recruiting | No outcome recorded |
| Phase 2 | NCT07255404 | Dec 2025 → Dec 2027 expected | pancreatic ductal adenocarcinoma | BioNTech SE | Recruiting | No outcome recorded |
| Phase 2 | NCT07133750 | Aug 2025 → Aug 2026 overdue | colorectal cancer | BioNTech SE | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06953089 | Jul 2025 → Jun 2030 expected | cancer | DualityBio Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT06841055 | Mar 2025 → Oct 2028 expected | non-small cell lung carcinoma | BioNTech SE | Recruiting | No outcome recorded |
| Phase 2 | NCT06837948 | Feb 2025 → Dec 2031 expected | non-small cell lung carcinoma | Shanghai Pulmonary Hospital, Shanghai, China | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06449222 | Aug 2024 → Aug 2028 expected | female breast carcinoma, triple-negative breast carcinoma | BioNTech SE | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06449209 | Aug 2024 → Jun 2027 expected | small cell lung carcinoma | BioNTech SE | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05756972 | Jun 2023 → Sep 2024 overdue | non-small cell lung carcinoma | BioNTech SE | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05844150 | Jun 2023 → May 2024 overdue | small cell lung carcinoma | BioNTech SE | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05879055 | May 2023 → Jan 2027 expected | neuroendocrine neoplasm | BioNTech SE | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05918107 | Aug 2022 → Mar 2026 | — | BioNTech SE | Completed | No outcome recorded |
| Phase 2 | NCT05879068 | May 2022 → Apr 2025 overdue | small cell lung carcinoma | BioNTech SE | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05864105 | Apr 2022 → Jul 2025 | hepatocellular carcinoma | BioNTech SE | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT07221149 | Mar 2026 → Nov 2030 expected | gastroesophageal adenocarcinoma | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07221357 | Dec 2025 → Feb 2030 expected | colorectal cancer | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06712316 | Jan 2025 → Feb 2029 expected | non-small cell lung carcinoma | BioNTech SE | Recruiting | No outcome recorded |
| Phase 36 trials | ||||||
| Phase 3 | NCT07361497 | Mar 2026 → Sep 2030 expected | non-small cell lung carcinoma | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 3 | NCT07361510 | Mar 2026 → Oct 2031 expected | non-small cell lung carcinoma | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 3 | NCT07173751 | Oct 2025 → Dec 2029 expected | breast neoplasm | BioNTech SE | Recruiting | No outcome recorded |
| Phase 3 | NCT06712355 | Feb 2025 → Dec 2028 expected | small cell lung carcinoma | BioNTech SE | Recruiting | No outcome recorded |
| Phase 3 | NCT06616532 | Nov 2024 → Jan 2027 expected | small cell lung carcinoma | BioNTech SE | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06419621 | Jun 2024 → Jul 2027 expected | triple-negative breast carcinoma | BioNTech SE | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07680764 Background | Aug 2026 → Sep 2028 expected | non-small cell lung carcinoma | Bristol-Myers Squibb | Not yet recruiting | No outcome recorded |
Press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-05-30 | BioNTech SE | Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial biontech.com ↗ |
| 2026-05-30 | Bristol-Myers Squibb | Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial bms.com ↗ |
| 2025-12-09 | BioNTech SE | BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer biontech.com ↗ |
| 2025-09-08 | BioNTech SE | First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity biontech.com ↗ |
| 2025-06-02 | BioNTech SE | BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types biontech.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 41 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pumitamig | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06618287 ↗ |
| Known as | BNT327 | “pumitamig, which is a cancer immunotherapy drug also known as BNT327 and PM8002” NCT07079631 ↗9“PM8002 (BNT327) is a bispecific antibody targeting PD-L1 and VEGF.” NCT07133750 ↗ “pumitamig (also known as BNT327 or PM8002)” NCT07147348 ↗ |
| Known as | PM8002 | “pumitamig, which is a cancer immunotherapy drug also known as BNT327 and PM8002” NCT07079631 ↗14“pumitamig (also known as BNT327 or PM8002)” NCT07147348 ↗ |
| Modality | Monoclonal antibody | “a Bispecific Antibody Targeting PD-L1 and VEGF-A” NCT05918445 ↗ |
| Route | Intravenous | “Administered I.V.” NCT05438329 ↗ |